Selective Adenosine A2A Receptor Antagonists for Parkinson's Disease
Solution Overview
Problem
Current treatments for Parkinson's disease and related movement disorders are inadequate, as they often lead to side effects such as involuntary movements, cognitive decline, and do not address the underlying neurodegenerative disorder, with existing therapies failing to provide consistent benefits and being associated with adverse effects like nausea and vomiting.
Innovation Solution
Development of selective adenosine A2A receptor antagonists that demonstrate high selectivity for the adenosine A2A receptor over A2B and A3 receptors, which are formulated into pharmaceutical compositions for administration to treat movement disorders like Parkinson's disease, Restless legs syndrome, and other neurodegenerative conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective adenosine A2A receptor antagonists are developed, then treatment effectiveness for movement disorders is improved, but the complexity of drug development increases
Solution Approach 1:
The patent segments the adenosine receptor antagonism function into a selective A2A receptor target, distinguishing it from A1, A2B, and A3 receptors. This segmentation allows for targeted therapy that addresses movement disorders specifically through A2A receptor blockade while avoiding off-target effects on other adenosine receptor subtypes, thereby improving treatment effectiveness without requiring complex polypharmacology approaches
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular characteristics that confer selectivity for the A2A receptor subtype. The chemical structures are optimized to interact preferentially with the A2A receptor binding site, creating a localized therapeutic effect in the striatum where A2A receptors are densely expressed, while minimizing interactions with other receptor subtypes in different tissue locations
2Productivity
If current Parkinson's disease treatments are used, then motor symptoms are temporarily relieved, but side effects such as involuntary movements and cognitive decline occur
Solution Approach 1:
The patent extracts the therapeutic benefit of adenosine receptor antagonism specifically from the A2A subtype, separating this beneficial effect from the side effects associated with non-selective anticholinergic and dopaminergic therapies. By taking out only the A2A receptor antagonism function, the treatment achieves motor symptom relief through a different mechanism that does not produce the involuntary movements and cognitive decline seen with traditional therapies
Solution Approach 2:
The invention converts the previously harmful or neutral role of adenosine A2A receptors in the striatum into a therapeutic target. By blocking these receptors, which normally inhibit dopamine release, the treatment enhances dopaminergic transmission and produces antiparkinsonian effects. This transforms the understanding of A2A receptors from potential side effect sources to beneficial therapeutic targets
3Adaptability or versatility
If non-selective adenosine receptor antagonists are used, then broad adenosine receptor blockade is achieved, but vascular and cardiac complications increase
Solution Approach 1:
The patent segments the adenosine receptor antagonism into a selective A2A subtype focus, excluding blockade of A1, A2B, and A3 receptors. This segmentation prevents the vascular and cardiac complications associated with A1 and A2B receptor antagonism, as these subtypes play important roles in cardiovascular regulation. The selective approach maintains therapeutic versatility for movement disorders while eliminating harmful cardiovascular effects
Solution Approach 2:
The invention applies local quality by concentrating the pharmacological effect specifically at the A2A receptor binding site in the striatum and other brain regions, while avoiding interaction with adenosine receptors in cardiovascular tissues. The molecular design ensures that the compound's affinity and selectivity are localized to the A2A receptor subtype, creating a region-specific therapeutic effect that spares cardiovascular systems from harmful blockade
Data Source
AI summary
Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.